Pediatric Low-Grade Gliomas Therapeutics Market Size, Share, and Industry Analysis, By Therapy (Chemotherapy, Targeted Therapy, and Others), By Drug (Dabrafenib, Trametinib, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2024-2032

Pediatric low-grade gliomas (pLGGs) are the most common type of brain tumor that occurs in children and represent around one-third of all types of pediatric central nervous system (CNS) tumors. According to the article published by the American Society of Clinical Oncology in April 2023, CNS tumors account for approximately 20.0% of pediatric cancer cases across the globe, and one-third of these cases are often pediatric low-grade gliomas.

The growth of the market is attributed to factors such as the increasing prevalence of pediatric brain tumors, growth in the number of diagnoses, and advancements in the number of research and drug development initiatives globally.

Based on the numerous ongoing studies, these gliomas can respond to multimodal therapy, which combines different kinds of drugs and therapies to control the disease progression. Growing knowledge of the molecular and genetic makeup of pediatric brain tumors is anticipated to drive the growth of personalized treatment approaches based on a combination of observable traits and genetic markers. Furthermore, there has been a growing number of targeted therapies that specifically address the molecular characteristics of these tumors. These factors are anticipated to drive the market in the coming years.

During the COVID-19 pandemic, the market witnessed negative growth due to the global lockdown restrictions. The lockdown resulted in a lower rate of diagnoses and treatment in 2020. Later, the relaxations in lockdown restrictions increased the number of pediatric cancer diagnosis and treatments. The market witnessed growth after the lockdown relaxations and reached the pre-pandemic levels by the end of 2022.  

The increasing incidence of pediatric low-grade gliomas diagnosis and the growing number of drug candidates in the pipeline is anticipated to grow the market significantly in the near future. Furthermore, rising initiatives by various organizations to increase pediatric low-grade glioma awareness amongst the general population are expected to increase the rate of diagnosis, and the demand for treatment is anticipated to grow over the forecast period.

• For instance, WHO launched the Global Initiative for Childhood Cancer (GICC) program in collaboration with the global childhood cancer community. This program aims to achieve at least a 60.0% survival rate for pediatric cancer, including low-grade gliomas worldwide, by 2030. Such initiatives boost the diagnosis and treatment, and market growth is expected in the coming years.

Segmentation

Key Insights

The report includes the following key findings:

• Prevalence of Pediatric Low-Grade Gliomas, by Key Countries/Region, 2023


• Pipeline Analysis By Key Players


• Key Industry Development- Acquisitions, Mergers, and Partnerships


• Impact of COVID-19 on the Market

Analysis by Therapy

Based on therapy, the market is classified into chemotherapy, targeted therapy and others. The targeted therapy segment is expected to witness significant growth in the coming years due to its higher efficacy. Rising approvals of new drugs targeting MAPK and BRAF pathways are anticipated to grow rapidly in the coming years. Moreover, extensive clinical investigations and pipeline drugs are expected to drive the segment growth in the near future.

• For instance, in November 2023, Children's Hospital Los Angeles completed a phase 2 clinical study of MEK162 for recurrent and progressive pediatric-low grade glioma treatment.

The others segment, which includes chemotherapy and immunotherapy, is expected to grow considerably in the coming years. Advancements in R&D and the increasing number of clinical evidence on the efficacy of chemotherapy and immunotherapy are anticipated to launch new drugs in the market, thereby contributing to the growth of the market.

Regional Analysis

The global market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for a significant revenue share in 2023. North America is expected to dominate the pediatric low-grade gliomas therapeutics market due to the increasing treatment options in the region and the presence of major players in the market. Moreover, a rising number of collaborations for clinical investigations is expected to enhance the region's market in the coming years.

• For instance, Novartis Pharmaceuticals, Pacific Pediatric Neuro-Oncology Consortium, and The Pediatric Low-Grade Astrocytoma (PLGA) Foundation collaboratively conducted a phase 2 clinical trial for the lead candidate PNOC 001 recurrent or progressive low-grade gliomas in pediatric patients. The trial is expected to end by July 2024. Such clinical investigations increase the chances of new and effective drug launches in the market and are anticipated to drive market growth.

Asia Pacific is expected to witness faster growth in pediatric low-grade glioma therapeutics. The market growth in the region can be attributed to the growing awareness among patients, an increasing number of diagnosis procedures, and an increasing number of clinical trials for R&D investments for the drug discovery and development of cancer drugs in the region are expected to propel the market growth over the forecast period.

Key Players Covered

The report includes key players, such as Novartis AG, AstraZeneca, Bristol-Myers Squibb Company, Pfizer, Teva Pharmaceutical Industries Ltd., and Servier Pharmaceuticals LLC.

Key Industry Developments

• In October 2023, Day One Biopharmaceuticals, Inc. announced that the FDA accepted the new drug application of tovorafenib, an oral, highly selective type II RAF kinase inhibitor, as a monotherapy for pediatric patients with relapsed or progressive low-grade glioma.


• In March 2023, Novartis AG received U.S. FDA approval for Tafinlar + Mekinist to treat pediatric patients with BRAF V600E low-grade glioma.